Novartis’s China Sales Grow 25 Percent
This article was originally published in PharmAsia News
Executive Summary
Novartis's China sales grew by 24.8 percent to reach 2.58 billion yuan ($362.7 million) in 2007; in particular, its animal health business jumped 50.9 percent. Beijing Novartis enjoyed sales of 2 billion yuan ($281 million), a rise of 27 percent. Six of Novartis's drug brands garnered over 100 million yuan ($14 million) each: anti-hypertensive medicine Diovan ranked number one in market share while sales of another anti-hypertensive Lotensin crossed 400 million yuan ($56.2 million). The company's vaccines introduced into China in mid-2006 reaped more than 50 million yuan ($7 million) in 2007. Novartis forecasts a growth of more than 20 percent for China in 2008. Its new R&D park in Shanghai is about to begin construction while its Suzhou plant will soon go into production. (Click here for more - Chinese Language)